PROTEOME SCIENCES PLC

Management Reports • Jan 6, 2026

National Storage Mechanism | Additional information

RNS Number : 7240N

Proteome Sciences PLC

06 January 2026

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. With the publication of this announcement, this information is now considered to be in the public domain.

6  January 2026

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Two further substantial contracts for Proteome Sciences

Proteome Sciences (AIM:PRM), is pleased to announce that following the Company's announcement dated 8 December 2025, the Company has secured two further substantial Good Clinical Laboratory Practice ("GCLP") contracts. The contracts have a combined value in excess of $1.5m.  Trial samples are expected to be shipped in late Q1 this year, with the major part of the contracts completed in 2026.

Commenting on the contracts, Richard Dennis, Chief Commercial Officer of Proteome Sciences said:

"We continue to experience strong interest in GCLP work from major biopharma clients in both the US and Europe and expect further orders to materialise in due course. These new contracts together with contracts previously secured provide a strong order book supporting our business  through  2026."

- Ends -

For further information:

Proteome Sciences plc

Dr. Ian Pike, Chief Scientific Officer

Tel: +44 (0)20 7043 2116

Richard Dennis, Chief Commercial Officer

SP Angel Corporate Finance LLP  (Nominated Adviser & Broker)
David Hignell/Richard Morrisom/Josh Ray  (Corporate Finance) Vadim Alexandre (Corporate Broking)	Tel: +44 (0) 20 3470 0470

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTUPUWAGUPQPGA